SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The Board appointed two new directors, Christopher Riccardi and Greg Voorhies, effective July 11, 2026, with terms expiring at the 2028 annual meeting. This is a clear director appointment disclosure under Item 5.02, and director appointments are material events affecting the composition and governance of the company's board.
View raw filing on EDGAR →The press release announces that Jinxin Technology has regained compliance with Nasdaq's Minimum Bid Price Requirement (Listing Rule 5550(a)(2)) after receiving a deficiency notice on January 29, 2026. The company evidenced a closing bid price at or above US$1.00 for 10 consecutive business days from June 26 to July 10, 2026, thereby curing the deficiency and closing the matter. This disclosure directly addresses a delisting risk — the company was previously non-compliant with a continued listing standard and faced potential delisting within a 180-day cure period, but has now remedied that condition.
View raw filing on EDGAR →ADI Global Distribution is disclosing an investor day event held on July 14, 2026, in connection with its pending spin-off from Resideo Technologies. The filing includes a press release and investor presentation outlining ADI's standalone strategy, financial framework, and medium-term financial targets (4-6% revenue CAGR, >10% Adjusted EBITDA CAGR by 2030, $80M+ in run-rate operating savings). While the spin-off itself is a material M&A activity, this Item 7.01 disclosure focuses on the strategic and operational positioning of ADI as an independent company rather than the separation transaction mechanics, making it primarily an operational/strategic disclosure.
View raw filing on EDGAR →The press release announces the Australian Patent Office's allowance of Patent Application No. 2021290439 for "Treatment of Advanced Metastatic Cancer," which strengthens Can-Fite's intellectual property portfolio for Namodenoson in hepatocellular carcinoma and pancreatic cancer. This is a material operational/strategic milestone that extends patent protection in a major international market and supports the company's most advanced oncology programs, but it does not fit the specific event categories of earnings release, M&A activity, executive changes, or other defined types. The patent allowance is a significant development for a clinical-stage biotech company's pipeline protection and market exclusivity.
View raw filing on EDGAR →This press release announces Steakholder Foods' U.S. market entry with its Perfecta™ Premium Plant-Based Meat product line, including the arrival of the first shipment and planned distribution through KeHE Distributors across dozens of retail outlets in the Northeastern USA. This is a material operational and strategic milestone—the company's entry into a major new market with a branded consumer product—but does not fit the specific event categories (M&A, earnings, executive changes, debt, etc.). It represents a significant business development and product commercialization event that would affect a reasonable investor's assessment of the company's growth prospects and market execution.
View raw filing on EDGAR →This press release announces a framework collaboration agreement with a leading global defense system integrator to supply radar systems for three projects, with initial orders already placed and additional orders anticipated in 2026-2027. The disclosure represents a material operational and commercial milestone—entry into a new high-value vertical (defense/homeland security) beyond automotive, with exclusive radar provider status and demonstrated customer commitment through initial deliveries. While not a discrete M&A transaction, it is a significant strategic partnership and customer win that would affect a reasonable investor's assessment of the company's growth prospects and market expansion.
View raw filing on EDGAR →This is a formal earnings release dated July 14, 2026, announcing Globavend's unaudited financial results for the six months ended March 31, 2026 (first half fiscal 2026). The document discloses revenue of US$14.8 million (8.0% increase), operating loss of US$369,978, net loss of US$30,887, and key operational metrics including 44% increase in average daily shipments. The release is material as it provides investors with periodic financial performance and operational updates essential to assessing the registrant's financial condition and business trajectory.
View raw filing on EDGAR →The filing discloses the appointment of Sarah M. Romano as Chief Financial Officer, effective August 3, 2026. While the disclosure also includes compensatory arrangements (base salary of $440,000, annual bonus eligibility, and stock option grant of 750,000 shares), the principal action is the appointment of a named executive officer to a C-suite position. The appointment of a CFO is material to investors as it affects the company's financial leadership and governance structure.
View raw filing on EDGAR →The disclosure describes a €20 million EIB loan that became due June 1, 2026, with the EIB reserving all rights and threatening enforcement action while negotiations continue. This represents a triggering event—a debt obligation in default or at imminent risk of default—that could accelerate financial obligations and materially affect the company's liquidity and financial position. While styled as "ongoing discussions," the EIB's reservation of rights and warning that enforcement is not contemplated only "while discussions remained ongoing" signals a covenant breach or technical default scenario typical of Item 2.04 disclosures.
View raw filing on EDGAR →The press release announces termination of a letter of intent for the acquisition of AI Financial Corporation's subsidiary Alt5 Sigma Canada, Inc. This is a material M&A event — the termination of a proposed transaction. The statement from Chief Strategy Officer Matthew Nicoletti explicitly states "Perpetuals has decided not to further pursue the acquisition" and "the earlier letter of intent has been terminated," which constitutes a material change in the status of a contemplated acquisition that would affect investor assessment of the company's strategic direction and capital allocation.
View raw filing on EDGAR →This is a press release announcing preliminary unaudited H1 2026 financial highlights, including revenue of approximately $11.4 million (up 115% versus H1 2025), cash position of $495 million, and reaffirmed FY 2026 guidance of 50%–100% revenue growth. The document explicitly states "Preliminary H1 2026 Financial Highlights (Unaudited)" and notes that "WISeKey expects to publish its full H1 2026 consolidated financial results in September 2026." This is a discrete earnings announcement for an interim period, not the periodic financial report itself.
View raw filing on EDGAR →The Company received notification from Nasdaq on July 13, 2026, granting an extension of 180 calendar days (until January 4, 2027) to regain compliance with the Minimum Bid Price Rule. The disclosure explicitly states that failure to regain compliance by that date will result in written notification of delisting. This is a material delisting-risk disclosure under Item 3.01 equivalent, as it directly threatens the Company's continued listing on Nasdaq.
View raw filing on EDGAR →PVH Corp. announced the appointment of Alexis Rollier as Chief Financial Officer, effective early September 2026, replacing interim CFO Melissa Stone. The filing discloses a detailed employment agreement with compensation terms including $850,000 base salary, bonus opportunities up to 200% of base, and equity awards totaling approximately $2.825 million in PSUs, RSUs, and sign-on awards. This is a material executive appointment to a principal officer position.
View raw filing on EDGAR →Jeanne Nguyen, the Company's Chief Accounting Officer, departed effective July 8, 2026. This is a clear executive departure of a named officer responsible for accounting functions, which is material to investors' assessment of the registrant's financial reporting controls and governance.
View raw filing on EDGAR →Churchill Capital Corp XI and Agility Robotics announced the confidential submission of a draft Form S-4 registration statement on July 13, 2026, in connection with their previously disclosed Merger Agreement. The filing discloses a material acquisition/business combination transaction expected to close in 2026, with approximately $620 million in gross proceeds, creating a publicly listed pure-play humanoid robotics company. This is a clear entry into a material merger and change of control transaction requiring shareholder approval.
View raw filing on EDGAR →The filing discloses the appointment of Paul Lapping as a director of Churchill Capital Corp XII effective July 13, 2026, along with his appointment to the compensation and audit committees and as audit committee chairperson. While the section also mentions director compensation agreements, the principal disclosed action is the appointment of a new director to the board and committee positions, making exec_appointment the most salient event type.
View raw filing on EDGAR →Oak Woods Acquisition Corp held an Extraordinary General Meeting on July 8, 2026, where shareholders voted to approve a Charter Amendment extending the business combination deadline from March 28, 2026 to March 28, 2027, with 2,398,953 votes in favor and 208,150 against, meeting the required two-thirds supermajority. The vote also approved an Adjournment Proposal, and 1,269,163 ordinary shares were tendered for redemption, resulting in a post-vote outstanding share count material to the company's equity base.
View raw filing on EDGAR →The disclosure centers on a revised letter agreement with CEO Stephen Willard that amends his compensatory arrangements, including removal of base salary deferral, establishment of an annual cash bonus program (45% target), modification of severance and change-of-control benefits, and acceleration of equity vesting from four years to three years. This is a material modification of executive compensation terms, not a departure or appointment.
View raw filing on EDGAR →This disclosure describes the consummation of Bleichroeder Acquisition Corp. III's initial public offering on July 8, 2026, involving the sale of 34.5 million units at $10.00 per unit (generating $345 million in gross proceeds) and concurrent private placement of 8.5 million warrants ($8.5 million). While IPOs are material capital-raising events, this is a blank-check/SPAC formation rather than a traditional operating company IPO or earnings release. The event does not fit neatly into the standard taxonomy categories (not earnings_release, not ma_activity, not debt_issuance in the traditional sense). The financial materiality is clear—$345 million raised—but the event type is ambiguous: it could be classified as a dilutive_issuance (equity capital raise), a financial_other (capital formation), or operational_other (strategic business event). Given the domain is financial but the specific type is unclear, other_material is most appropriate.
View raw filing on EDGAR →This is a clear earnings release disclosing Rocky Mountain Chocolate Factory's quarterly financial results for the three months ended May 31, 2026. The press release reports total revenue of $6.1 million, a net loss of $1.2 million ($(0.12) per share), and negative EBITDA of $(0.6) million, with detailed consolidated statements of operations and balance sheets attached as Exhibit 99.1. The deterioration in results compared to the prior year quarter (net loss increased from $(0.3) million to $(1.2) million) is material to investors' assessment of the company's financial condition.
View raw filing on EDGAR →The filing discloses the exercise of an underwriter option to purchase an additional 1,500,000 Class A ordinary shares, generating $30.0 million in gross proceeds. This is a dilutive equity issuance that increases share count and raises capital, fitting the definition of a dilutive_issuance. The materiality is clear given the substantial capital raised and shareholder dilution involved.
View raw filing on EDGAR →This news release announces the peer-reviewed publication of Phase II clinical trial data for CardiolRx™ in the Journal of the American Heart Association, with the pivotal Phase III MAVERIC trial nearing completion. The publication of positive Phase II results in a peer-reviewed journal is a material operational/clinical milestone for a late-stage biopharmaceutical company, as it strengthens the scientific foundation for the ongoing Phase III pivotal trial and demonstrates clinical efficacy and safety. This is a discrete clinical/operational event distinct from periodic financial reporting.
View raw filing on EDGAR →Domino's appointed Michael C. Creedon, Jr. (former CEO of Dollar Tree) and Anneliese Olson (former President of HP's Imaging, Printing and Solutions division) to the Board of Directors effective July 15, 2026, increasing the Board size from eight to ten directors.
View raw filing on EDGAR →Corie S. Barry was appointed as Lead Independent Director of Domino's Board on July 14, 2026, replacing Richard L. Federico in that governance leadership role.
View raw filing on EDGAR →Vale's Board of Directors elected Mr. Wilfred Theodoor Bruijn, an independent board member, to serve as Chairman of the Board of Directors, filling a vacancy that arose on July 6, 2026. The appointment of a Chairman is a material governance event affecting the registrant's leadership structure and would influence a reasonable investor's assessment of the company's governance and direction.
View raw filing on EDGAR →The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of San Francisco. Schedule A details three specific debt issuances with trade dates in July 2026, including a $15 million fixed-rate bond, a $1 billion variable-rate floater, and a $565 million variable-rate floater, totaling approximately $1.58 billion in new debt obligations. This is a classic Item 2.03 debt issuance disclosure.
View raw filing on EDGAR →The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Des Moines. Schedule A lists multiple debt securities with trade dates of 7/8/2026 through 7/10/2026, including fixed-rate bonds and variable-rate floaters with principal amounts ranging from $10 million to $1.5 billion. The Bank explicitly states that "consolidated obligations issuance is material to the Bank," and Item 2.03 is the standard disclosure vehicle for debt issuance under 8-K rules.
View raw filing on EDGAR →The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Topeka. Schedule A details multiple debt securities issued on trade dates in July 2026, including fixed-rate bonds (ranging from 4.3% to 5.1% coupons) and variable-rate floaters totaling approximately $3.3 billion in principal. This is a classic debt issuance disclosure under Item 2.03, and the registrant explicitly acknowledges that "consolidated obligations issuance is material to the FHLBank."
View raw filing on EDGAR →The filing discloses the creation of multiple direct financial obligations through the issuance of Consolidated Bonds by the Federal Home Loan Bank of Cincinnati. Schedule A lists 14 separate bond issuances with trade dates in July 2026, ranging from $1 million to $50 million in principal amount, with maturities from 2027 to 2046 and coupon rates from 4.125% to 5.890%. The filing explicitly states that "Consolidated Obligations issuance is material to the FHLB," and Item 2.03 is the standard disclosure vehicle for debt issuances. This represents a material creation of direct financial obligations.
View raw filing on EDGAR →The filing discloses the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Chicago, with Schedule A detailing multiple debt securities issued on trade dates of 7/8/2026, 7/9/2026, and 7/10/2026, totaling approximately $115 million in principal across multiple tranches with varying maturity dates and coupon rates. The Bank explicitly states that "consolidated obligations issuance is material to the Bank," and Item 2.03 is the standard disclosure vehicle for creation of direct financial obligations.
View raw filing on EDGAR →Frank Nitkiewicz, the Executive Vice President, Chief Operating Officer and Chief Financial Officer, notified the Bank on July 8, 2026 of his intent to retire by March 31, 2027. The disclosure centers on the departure of a senior executive holding critical financial and operational roles (principal financial officer and principal operating officer). While the filing notes the Bank's intention to search for a successor, the principal disclosed action is Nitkiewicz's retirement, making this an exec_departure event.
View raw filing on EDGAR →The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Boston. Schedule A details four specific debt issuances with trade dates in July 2026, ranging from $10 million to $50 million in principal amount, with maturity dates between 2027 and 2031. This is a classic debt_issuance event under Item 2.03, representing new direct financial obligations created by the registrant.
View raw filing on EDGAR →The filing discloses the Federal Home Loan Bank of Indianapolis becoming the primary obligor on consolidated obligation bonds with a par value of $15,000,000, a 5-year maturity (7/14/2026 to 7/14/2031), and a 4.875% fixed coupon. This is a direct creation of a new financial obligation under Item 2.03, meeting the definition of debt issuance. The settlement date of 7/14/2026 confirms the obligation has been incurred.
View raw filing on EDGAR →The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds by the Federal Home Loan Bank of Dallas. Schedule A details three bond issuances with trade dates of 7/8/2026 and 7/9/2026, totaling $50 million in par amount, with maturities ranging from 2028 to 2051. This is a classic debt_issuance event under Item 2.03, representing new direct financial obligations of the registrant.
View raw filing on EDGAR →Mesoblast announced achievement of its target enrollment of 300 patients in the MSB-DR004 pivotal Phase 3 trial for rexlemestrocel-L in chronic low back pain. This is a material clinical development milestone—the trial is now fully enrolled and powered for success, with top-line results expected in mid-2027. The announcement indicates progress toward a potential blockbuster indication (>US$10 billion peak revenue potential) and positions the company for regulatory filing. While this is an operational/clinical milestone rather than a discrete event like M&A or exec change, it materially affects investor assessment of the company's pipeline and commercial prospects.
View raw filing on EDGAR →The filing discloses the appointment of Michael Jennings and Zamir Rauf to the Board of Directors of the General Partner, effective July 14, 2026, with detailed descriptions of their qualifications and committee assignments. While the disclosure also includes compensatory arrangements (phantom units and cash fees) and the resignations of two directors, the principal action is the appointment of two new independent directors with substantial energy-sector experience. This is material to investors as board composition affects governance and oversight.
View raw filing on EDGAR →Genprex received a Nasdaq delisting notice on June 10, 2026, for failure to maintain the minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company has requested a hearing before a Nasdaq Hearings Panel and is implementing a 1-for-22 reverse stock split effective July 16, 2026, to regain compliance.
View raw filing on EDGAR →Genprex stockholders approved a 1-for-22 reverse stock split on June 18, 2026, which was effectuated via Certificate of Amendment filed July 13, 2026. The reverse split materially affects shareholder rights and capital structure by consolidating shares and altering per-share metrics.
View raw filing on EDGAR →CervoMed announced clinical, plasma biomarker, and imaging data for neflamapimod presented at the Alzheimer's Association International Conference 2026, including Phase 2b RewinD-LB trial results, pharmacokinetic-pharmacodynamic analyses, and Phase 2 study findings for an 80 mg BID dose. These data support the company's planned Phase 3 trial design and dose selection, representing a material clinical development milestone for the company's lead drug candidate.
View raw filing on EDGAR →Loop Industries issued a press release on July 14, 2026 announcing its consolidated financial results for the first quarter of fiscal year 2027, including revenues of $179 thousand, net loss of $3,385 thousand, and cash position of $1,063 thousand. The filing explicitly states "Loop Industries, Inc. (the 'Company') issued a press release announcing its financial results for the first quarter of fiscal year ending February 28, 2027" with the press release attached as Exhibit 99.1, which is the standard format for an earnings release disclosure under Item 2.02.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder vote results from a Special Meeting held on July 13, 2026. The filing reports final voting tallies for two proposals: (1) approval of a reverse stock split at a ratio to be determined by the Board (9,131,707 for, 115,909 against), and (2) approval of an amendment to increase authorized capital stock from 46 million to 1.001 billion shares (6,700,459 for, 89,041 against). Both proposals passed with overwhelming majorities and are material to investors as they affect share structure and capitalization.
View raw filing on EDGAR →Bridgeline Digital entered into an at-the-market (ATM) offering agreement with WestPark Capital to sell shares of common stock on a registered basis under Form S-3. While technically registered (not unregistered), ATM offerings are economically equivalent to dilutive equity issuances and represent a material capital-raising mechanism that creates ongoing dilution risk to existing shareholders. The agreement grants the company discretion to sell shares at market prices, making this a material financing event typical of small-cap issuers raising capital.
View raw filing on EDGAR →The filing discloses unaudited condensed consolidated interim financial statements and MD&A for the three and six months ended May 31, 2026, filed via Form 6-K by the parent company GoldMining Inc. on July 14, 2026. Although furnished under Item 7.01 (Regulation FD Disclosure) rather than Item 2.02, the core disclosure is interim financial results—a periodic earnings release. The statements show a net loss of $16.5 million for the six-month period and include comprehensive income data, cash flows, and balance sheet information typical of an interim earnings disclosure.
View raw filing on EDGAR →QumulusAI issued fiscal year 2026 guidance disclosing forward ARR of $300 million (~30x growth) and 18 MW of capacity with line of sight to 2.5 GW by 2027. While this resembles an earnings release or forward guidance, it is disclosed under Item 7.01 (Regulation FD Disclosure) as an "investor outlook update" rather than as a formal earnings release tied to quarterly/annual results. The disclosure centers on operational metrics (ARR and capacity expansion) and strategic business outlook rather than historical financial results, making it an operational/strategic disclosure material to investors assessing the company's growth trajectory and infrastructure deployment plans.
View raw filing on EDGAR →Ms. Anya Hamill, the Chief Financial Officer, notified the Company on July 9, 2026 of her resignation effective August 31, 2026. The disclosure centers on the departure of a named executive officer from a material position. The filing explicitly states there are no disagreements or issues regarding financial statements or internal controls, indicating a routine departure rather than a governance crisis, but CFO departures are material events that affect investor assessment of the registrant's financial leadership and continuity.
View raw filing on EDGAR →This is a proxy statement and notice of shareholder meetings (Class B Meeting and Extraordinary General Meeting) scheduled for July 22, 2026. The document discloses multiple governance proposals including: (1) variation of Class B Ordinary Share voting rights from 20 to 100 votes per share; (2) increase of authorized shares from 600 million to 5 billion; (3) adoption of amended memorandum and articles of association; (4) share consolidation authorization up to 2,000-for-1 ratio. These are material governance and capital structure changes requiring shareholder approval, making this a governance event that does not fit a specific named category (not a vote result, but the notice/proxy for upcoming votes).
View raw filing on EDGAR →Youxin Technology announced a non-binding term sheet to make a strategic investment of US$20 million in RiverBit Holding Limited to acquire a 10% equity interest upon achievement of operating milestones (2,000 daily users and US$100 million daily trading volume within three months of launch). Although non-binding and contingent on due diligence and definitive agreements, this represents a material acquisition of a minority equity interest in a third party, which falls within the scope of M&A activity disclosures. The investment amount and strategic nature would affect a reasonable investor's assessment of the company's capital allocation and business strategy.
View raw filing on EDGAR →The filing's primary disclosure is Item 5.07, which reports the results of the July 9, 2026 Annual Meeting of Stockholders, including voting outcomes on four proposals: director election (Jeff Hargroves), auditor ratification (KPMG LLP), equity plan amendment (625,000 additional shares), and meeting adjournment. While the filing also contains Item 5.02 disclosures regarding board structure changes and equity plan amendments, the central event is the shareholder vote results with specific vote tallies for each proposal, making shareholder_vote_results the most salient classification.
View raw filing on EDGAR →Almonty announced an amendment to its long-term offtake agreement with Global Tungsten & Powders that extends the contract term from 15 to 21 years, increases contracted volumes by 40% to 4.41 million MTU, and improves pricing by 6.3%, resulting in US$490 million in total contracted annual revenue at current pricing. This is a material operational and commercial event—a significant expansion of a key supply contract covering approximately 90% of Phase I production from the Sangdong Mine—that would affect a reasonable investor's assessment of the company's revenue visibility and strategic positioning in the tungsten market.
View raw filing on EDGAR →CL Workshop Group Limited entered into a securities purchase agreement on July 14, 2026, for a private placement of 12,300,000 units at US$0.20 per unit, generating approximately US$2.46 million in gross proceeds plus potential additional proceeds of US$9.225 million upon warrant exercise. This is a classic dilutive issuance of unregistered equity securities (ADSs and warrants) sold in reliance on Section 4(a)(2) and Regulation S exemptions, materially affecting shareholder ownership and the capital structure.
View raw filing on EDGAR →